Straits Times Index
3,330.09 +11.64 (+0.35%) S&P 500
5,283.21 -21.51 (-0.41%) Dow
38,726.31 -343.28 (-0.88%) Nasdaq
16,925.03 +4.23 (+0.03%) Bitcoin USD
67,542.02 -2,329.66 (-3.33%) CMC Crypto 200
1,472.16 -24.30 (-1.62%)
MRK Jan 2026 100.000 put
| Previous close | 3.0300 |
| Open | 3.0900 |
| Bid | 3.4500 |
| Ask | 4.2500 |
| Strike | 100.00 |
| Expiry date | 2026-01-16 |
| Day's range | 3.0300 - 3.0900 |
| Contract range | N/A |
| Volume | |
| Open interest | 468 |
BenzingaMerck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED)
Editor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead of ‘Lung’ cancer. Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from hase 3 KEYNOTE-522 trial of Keytruda in high-risk early-stage triple-negative breast cancer (TNBC). The study evaluated Keytruda in combination with chemotherapy as a pre-operative (neoadjuvant) treatment and then continuing as a single agent after surgery (adjuvant). The study met its overall survival (OS) endpoint.
Simply Wall St.Is Merck & Co., Inc.'s (NYSE:MRK) Recent Performance Underpinned By Weak Financials?
Merck (NYSE:MRK) has had a rough month with its share price down 1.3%. To decide if this trend could continue, we...
Business WireMerck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)
RAHWAY, N.J., May 28, 2024--Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer
